The global Gene Editing Market was valued at $5.1 billion in 2022 and is projected to reach $16.2 billion by 2030, growing at ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven by a mostly inherited mutation.

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

timing and frequency of germline and somatic testing for HRRm, and line of therapy where novel hormonal therapies and/or PARP ...

Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...

AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval by the Scottish ...

Germline development is the development of the ... the H3K79 methyltransferase DOT1L has opposite effects on autosomal and X-linked gene expression depending on local chromatin enrichment in ...

Collins, along with Matthew Lau ’25, developed the affordable CRISPRKit to make CRISPR gene-editing technology accessible to high school students underrepresented in the sciences. The kit was ...

Copyright 2025 The Associated Press. All Rights Reserved. Chicago Chess Records producer Gene Barge attends a screening of the film “Cadillac Records,” about ...

Although these diseases were initially treated by transplantation of allogeneic hematopoietic stem cells, the past 20 years has shown that these conditions are correctable by gene therapy.

The one-off gene therapy, known as exagamglogene autotemcel (or ‘exa-cel’), has been approved for use on the NHS in England from today (Friday 31 January) by the National Institute for Health and Care ...